英国BSR成人系统性红斑狼疮管理指南2018基线多中心审计
共审计1003例患者的1021次就诊,发现28.5%患者疾病活动,49%就诊记录使用泼尼松龙,多个审计标准合规率低于60%;专科门诊在尿蛋白定量和血压记录等方面合规率更高。
要点
- 近半数就诊记录使用泼尼松龙,包括28.5%疾病评估为不活动的就诊。
- 疾病活动正式评估、降低药物毒性及合并症防护等标准合规率低于60%。
- 专科门诊在尿蛋白定量和血压记录上合规率高于普通门诊。
核心结论
- 审计显示SLE疾病控制和减少糖皮质激素毒性方面存在显著未满足需求,也是改善国家指南依从性的机会。
- 专科门诊在肾炎筛查方面表现更好,支持更广泛采用该服务模式。
研究设计与样本
- 回顾性审计2018年2月至6月间任意4周内就诊的SLE病例,评估前一次就诊的照护。
- 比较普通与专科CTD/血管炎门诊、专科与非专科中心,并对显著性水平应用Bonferroni校正。
主要发现
- 286例(28.5%)患者有活动性疾病。
- 497次(49%)就诊记录患者正在接受泼尼松龙,其中28.5%的就诊疾病评估为不活动。
- 与普通门诊相比,专科门诊在适当尿蛋白定量标准上合规率更高(85.1% vs 78.1%,P ≤ 0.001)。
- 专科中心在BILAG生物制剂登记招募(89.4% vs 44.4%,P ≤ 0.001)和血压记录(95.3% vs 84.1%)上合规率更高。
关键数值与推荐
- 审计标准源自近期发布的BSR成人SLE管理指南、NICE贝利尤单抗技术评估及NHS England利妥昔单抗临床委托政策。
- 疾病活动正式评估、降低药物毒性及合并症和损伤防护相关审计标准的记录合规率低于60%的就诊。
临床怎么用
- 应加强SLE疾病活动正式评估、糖皮质激素毒性管理及合并症防护的规范记录。
- 专科CTD/血管炎门诊模式可提高肾炎筛查等标准合规率,值得推广。
局限性
- 为回顾性审计,仅评估前一次就诊的照护记录。
- 审计标准合规性基于病历记录,可能受记录完整性影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the baseline care provided to patients with SLE attending UK Rheumatology units, audited against standards derived from the recently published BSR guideline for the management of adults with SLE, the NICE technology appraisal for belimumab, and NHS England's clinical commissioning policy for rituximab. METHODS: SLE cases attending outpatient clinics during any 4-week period between February and June 2018 were retrospectively audited to assess care at the preceding visit. The effect of clinical environment (general vs dedicated CTD/vasculitis clinic and specialized vs non-specialized centre) were tested. Bonferroni's correction was applied to the significance level. RESULTS: Fifty-one units participated. We audited 1021 episodes of care in 1003 patients (median age 48 years, 74% diagnosed >5 years ago). Despite this disease duration, 286 (28.5%) patients had active disease. Overall in 497 (49%) clinic visits, it was recorded that the patient was receiving prednisolone, including in 28.5% of visits where disease was assessed as inactive. Low documented compliance (<60% clinic visits) was identified for audit standards relating to formal disease-activity assessment, reduction of drug-related toxicity and protection against comorbidities and damage. Compared with general clinics, dedicated clinics had higher compliance with standards for appropriate urine protein quantification (85.1% vs 78.1%, P ≤ 0.001). Specialized centres had higher compliance with BILAG Biologics Register recruitment (89.4% vs 44.4%, P ≤ 0.001) and blood pressure recording (95.3% vs 84.1%). CONCLUSIONS: This audit highlights significant unmet need for better disease control and reduction in corticosteroid toxicity and is an opportunity to improve compliance with national guidelines. Higher performance with nephritis screening in dedicated clinics supports wider adoption of this service-delivery model.
引用
- Pearce FA, Rutter M, Sandhu R, et al. BSR guideline on the management of adults with systemic lupus erythematosus (SLE) 2018: baseline multi-centre audit in the UK. Rheumatology (Oxford). 2021. PMID: 33291150. doi:10.1093/rheumatology/keaa759
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。